Company
Caribou Biosciences, Inc. (CRBU)
Standardized SEC financial data for Caribou Biosciences, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001619856 · NASDAQ · Biological Products, (No Diagnostic Substances).
Operating margin
-1000.0%
Net margin
-1000.0%
Revenue growth (YoY)
11.7%
Return on equity
-121.2%
Free cash flow
-$112.4M
Current ratio
5.71×
EPS (diluted)
$-1.59
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $9.6M | $13.9M | $34.5M | $10.0M | $11.2M |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.0M | $413.5M | $317.0M | $372.4M | $249.4M | $142.8M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$33.2M | -$32.5M | -$91.0M | -$93.3M | -$138.2M | -$111.0M |
| Capital expenditures |
Get CRBU data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/CRBU/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/CRBU/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"